TCRX FY 2024 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-86.6% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$135M-4787.7% margin

Net Income

-$127M-4527.7% margin

EPS (Diluted)

$-1.14

Cash Flow

Operating Cash Flow

-$111M

Free Cash Flow

-$115M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$371M

Total Liabilities

$130M

Stockholders' Equity

$241M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$21M	-86.6%
Gross Profit	$3M	$21M	-86.6%
Operating Income	-$135M	-$93M	-44.3%
Net Income	-$127M	-$89M	-42.9%